In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CFSAN program priorities

This article was originally published in The Rose Sheet

Executive Summary

FDA issues request for input on Center for Food Safety and Applied Nutrition's 2003 program priorities in June 21 Federal Register notice. Comments must be submitted to FDA by August 20, agency says. CFSAN's program work plan, which will run from Oct. 1 until Sept. 30, 2003, will be available in the fall, according to FDA. Agency anticipates initiatives in 2003 will be aimed at increasing security of U.S. food supply and notes "progress will continue towards development of a centralized adverse event reporting system"...

You may also be interested in...



CFSAN Colour Index Nomenclature Acceptance Tops CTFA Priority Request

FDA should permit the use of the European-developed Colour Index nomenclature for color additive labeling in place of existing agency requirements, according to the Cosmetic, Toiletry and Fragrance Association

Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round

Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.

Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children

Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS010386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel